Table 1.

Pertinent Baseline Characteristics

VariableStatin MonotherapyCombination Therapy
n16961718
Age (SD), y63.7 (8.7)63.7 (8.8)
Female251 (14.8)253 (14.7)
Risk factors, %
 Diabetes mellitus570 (33.6)588 (34.2)
 Hypertension1189 (70.1)1250 (72.8)
 Metabolic syndrome1353 (79.8)1414 (82.3)
History, %
 Myocardial infarction955 (56.3)968 (56.3)
 Cerebrovascular disease (stroke/TIA)362 (21.3)358 (20.8)
 Atrial fibrillation129 (7.6)122 (7.1)
 PVD231 (13.6%)234 (13.6%)
Medications at baseline, %
 Niacin*338 (19.9)324 (18.9)
 Statin1601 (94.4)1595 (92.8)
 ASA/antiplatelet agents1595 (94.0)1637 (95.3)
 ACE inhibitors/ARB1271 (74.9)1258 (73.2)
 BP-lowering meds (β-blockers/ACE inhibitors/ARB/calcium channel blockers/diuretics)1615 (95.2)1642 (95.6)
LDL cholesterol, mmol/L; mean (SD)1.91 (0.59)1.92 (0.61)
Triglycerides, mmol/L; median (interquartile range)1.84 (1.48–2.44)1.89 (1.48–2.47)
HDL cholesterol, mmol/L; mean (SD)0.90 (0.14)0.89 (0.14)
ApoB, mmol/L; mean (SD)0.83 (0.21)0.83 (0.20)
ApoA, mmol/L; mean (SD)1.24 (0.16)1.22 (0.16)
ApoB/ApoA ratio0.68 (0.18)0.69 (0.18)
Total/HDL Cholesterol ratio4.2 (1.0)4.3 (1.0)
Lp(a), µmol/L; median (interquartile range)1.16 (0.47–4.29)1.29 (0.48–4.51)
  • Number (percent) for categorical variables or mean (SD) for continuous normally distributed variables and median (interquartile range) for continuous and skewed variables. ACE indicates angiotensin-converting enzyme; ApoA, apolipoprotein A; ApoB, apolipoprotein B; ARB, angiotensin receptor blocker; ASA, aspirin; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PVD, peripheral vascular disease; and TIA, transient ischemic attack.

  • * Discontinued 30 days before enrollment.